55 results about "Mycobacterial disease" patented technology

A number of protein and glycoprotein antigens secreted by Mycobacterium tuberculosis (Mtb) have been identified as “early” Mtb antigens on the basis early antibodies present in subjects infected with Mtb prior to the development of detectable clinical disease. Epitope-bearing peptide fragments of these early Mtb antigens, in particular of an 88 kDa secreted protein, GlcB (SEQ ID NO:106) and of Mtb antigen MPT51 (SEQ ID NO:107) have been identified. These peptides, variants thereof, peptide multimers thereof that include two or more repeats of one or more of the peptides, and fusion polypeptides that include early Mtb antigenic proteins, peptides or both, are useful in immunoassay methods for early, rapid detection of TB in a subject. Preferred immunoassays detect the antibodies in the subject's urine. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mtb antibodies. The antigenic proteins and peptides are also used in vaccine compositions.

The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum. In particular, compounds are claimed in which, independently from each other, R1 is bromo, p=1, R2 is alkyloxy, R3 is optionally substituted naphthyl or phenyl, q=1, R4 and R5 each independently are hydrogen, methyl or ethyl, R6 is hydrogen, r is equal to 0 or 1 and R7 is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.

The invention relates to a disinfectant, in particular to a preparation and application of a compound disinfectant containing various disinfection components, and the compound disinfectant comprises the following components by weight percent: 0.01%-5% of guanidine compound, 0.01%-10% of quaternary ammonium salt compound, 0.01%-2% of trilon B, 0.01%-2% of 2-bromo-2-nitro-1,3-propanediol, 0.01%-10% of monohydric alcohol, 0%-30% of dihydric alcohol, 0%-30% of polyhydric alcohol and the balance of water. The invention further provides the application of the compound disinfectant composition, the compound disinfectant composition can be applied in disinfection of object surfaces, air-conditioning systems, environments and air in the field of public health, the field of food processing and the filed of medical sanitation through a multifunctional atomizing machine for effectively preventing and killing vegetative forms of bacteria, mycobacteria, viruses, fungi and spores thereof, and the like, can be applied in the disinfection of the air in automobiles, the object surfaces and the air-conditioning systems through the multifunctional atomizing machine for effectively preventing and killing the vegetative forms of the bacteria, the mycobacteria, the viruses and the like, can be applied in the disinfection of the air in train carriages, cabins and the automobiles and the disinfection of objects and the environments through the multifunctional atomizing machine for effectively preventing and killing the vegetative forms of the bacteria, the mycobacteria, the viruses and the like, can be further applied in the disinfection of the environments, indoor spaces and the object surfaces in the field of livestock and poultry breeding through the multifunctional atomizing machine for effectively preventing and killing the vegetative forms of the bacteria, the mycobacteria, the viruses, the fungi and the spores thereof, and the like.

The present invention relates to mycobacterial lipoarabinomannan cap-specific mannosyl transferases and nucleic acid encoding such transferases. The invention further relates to Mycobacteria in which the lipoarabinomannan cap-specific mannosyl transferases have been inactivated and that therefore express mannose cap-deficient lipoarabinomannan. Such Mycobacteria with mannose cap-deficient lipoarabinomannan may be used as more effective vaccines against mycobacterial diseases as they lack the immunosuppressive action of the mannose cap.

The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal / permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.